



Response under 37 C.F.R § 1.116
Expedited Procedure
Examining Group: 1625

AF

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Myra Gilligan et al.

Serial No. : 10/552,931 Case No.: T1629YP

Art Unit:
1625

Filed : October 11, 2005

Examiner:
David K. O'Dell

FOR : 4-ARYLSULPHONYLPIPERIDINE DERIVATIVES
FOR ANTAGONISM OF THE 5-HT2A RECEPTOR

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT UNDER 37 C.F.R. §1.116

Sir:

With reference to the Official action of March 31, 2008, made final, for which a response is permitted by June 30, 2008, the Applicants respectfully request reconsideration of the application in view of the following amendments and remarks in the hope that they will place the application in condition for allowance or at least in better condition for appeal. Any additional fees associated with this Response may be charged to Merck Deposit Account No. 13-2755.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this response. **Remarks** begin on page 5 of this response.

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS
FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO:
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

ON THE DATE APPEARING BELOW:

BY:

DATE: 26 JUNE 2008